These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6808669)

  • 1. [Economic effectiveness of prophylactic and therapeutic measures in cardiovascular diseases].
    Roĭtman MP; Lunskaia LL
    Sov Zdravookhr; 1982; (5):50-4. PubMed ID: 6808669
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of cardiovascular disease spending.
    Miller G; Cohen JT; Roehrig C
    J Am Coll Cardiol; 2012 Nov; 60(20):2123-4. PubMed ID: 23137531
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating Value Series.
    Ho PM
    Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28093400
    [No Abstract]   [Full Text] [Related]  

  • 4. Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being.
    Antman EM; Harrington RA
    JAMA; 2012 Nov; 308(17):1743-4. PubMed ID: 23117771
    [No Abstract]   [Full Text] [Related]  

  • 5. A review of the economic evaluation of interventions for cardiovascular diseases in Spain.
    Catalá-López F; García-Altés A; Alvarez-Martín E; Gènova-Maleras R; Morant-Ginestar C; Fernández de Larrea-Baz N
    Farm Hosp; 2012; 36(3):163-5. PubMed ID: 22024013
    [No Abstract]   [Full Text] [Related]  

  • 6. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

  • 7. The cost effectiveness of preventing cardiovascular diseases.
    Grover SA
    Can J Cardiol; 1999 Dec; 15 Suppl G():114G-6G. PubMed ID: 10692671
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cost effectiveness analysis of cholesterol-reducing measures. Economic analysis of a treatment program].
    Eggen AE; Maehlumshagen PM; Westerheim AB; Kristiansen IS
    Tidsskr Nor Laegeforen; 1989 Mar; 109(7-8):857-63. PubMed ID: 2495578
    [No Abstract]   [Full Text] [Related]  

  • 9. The economics of cardiovascular disease in the United States.
    Chen J; Rizzo JA
    Crit Care Clin; 2012 Jan; 28(1):77-88, vi. PubMed ID: 22123100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Socioeconomic aspects of therapy of cardiovascular diseases].
    Lauterbach KW
    Herz; 2000 Aug; 25(5):473-5. PubMed ID: 10992995
    [No Abstract]   [Full Text] [Related]  

  • 11. Catastrophic healthcare expenditure during economic recession in the field of cardiovascular disease.
    Fanourgiakis J; Kanoupakis E
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):5-8. PubMed ID: 24308449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa.
    Gaziano TA
    Heart; 2008 Feb; 94(2):140-4. PubMed ID: 18195120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in medical expenditure according to drug prices.
    Ueshima H
    Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
    [No Abstract]   [Full Text] [Related]  

  • 14. The year in epidemiology, health services research, and outcomes research.
    Hlatky MA; Heidenreich P
    J Am Coll Cardiol; 2009 Dec; 54(25):2343-51. PubMed ID: 20082921
    [No Abstract]   [Full Text] [Related]  

  • 15. How much does Europe invest in the treatment of cardiovascular diseases?
    Tendera M
    Eur Heart J; 2006 Jul; 27(13):1521-2. PubMed ID: 16757493
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prevention of cardiovascular diseases:a medical-economic approach].
    Therapie; 2001; 56(2):125-30. PubMed ID: 11484713
    [No Abstract]   [Full Text] [Related]  

  • 17. Quality of Methods and Results Reporting in Cost-effectiveness Analyses of Cardiovascular Interventions.
    Ridao M; Catalá-López F
    Rev Esp Cardiol (Engl Ed); 2016 Sep; 69(9):876-7. PubMed ID: 27445192
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with Type 2 diabetes: results from a randomized controlled trial.
    Simpson SH; Lier DA; Majumdar SR; Tsuyuki RT; Lewanczuk RZ; Spooner R; Johnson JA
    Diabet Med; 2015 Jul; 32(7):899-906. PubMed ID: 25594919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On reducing cardiovascular disease to a rarity: clinical strategies and their cost-effectiveness.
    Lewis B; Watts GF; Sullivan DR
    Heart Lung Circ; 2010 Apr; 19(4):225-7. PubMed ID: 20149730
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost and effectiveness of cardiovascular prevention.
    Boyar A
    Am J Cardiol; 2007 Nov; 100(9):1492-4; author reply 1494-5. PubMed ID: 17950815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.